AstraZeneca

169 articles with AstraZeneca

• Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

  1/24/2022

  Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.

• Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen

  1/17/2022

  Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen.

• BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure

  1/13/2022

  BenevolentAI , a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca.

• TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

  1/13/2022

  AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US.

• Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets

  1/13/2022

  Scorpion Therapeutics, Inc. today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

• Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators

  1/3/2022

  Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.

• EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities

  12/23/2021

  EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities.

• FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma

  12/22/2021

  Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE ™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.

• FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

  12/17/2021

  Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

• TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma

  12/17/2021

  AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.

• EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study

  12/16/2021

  AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.

• Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

  12/14/2021

  Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).

• FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19

  12/10/2021

  Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19.

• EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

  12/9/2021

  AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US for the pre-exposure prophylaxis (prevention) of COVID-19, with first doses expected to become available very soon.

• Datopotamab Deruxtecan Continues to Show Promising Durable Response and Disease Control in Patients with Metastatic Triple Negative Breast Cancer

  12/7/2021

  New data from the TROPION-PanTumor01 phase 1 trial of datopotamab deruxtecan (Dato-DXd), continue to show encouraging durable tumor response and disease control in patients with metastatic triple negative breast cancer (TNBC) with disease progression following standard treatment.

• AstraZeneca Reinforces Leadership in Breast Cancer at SABCS 2021 With New Data Underscoring Ambition to Redefine Cancer Care

  12/3/2021

  AstraZeneca will underscore its ambition to redefine care with new data from across its portfolio of innovative medicines at the 2021 San Antonio Breast Cancer Symposium (SABCS) December 7-10, 2021.

• LYNPARZA® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer

  11/30/2021

  LYNPARZA ® (olaparib) Granted Priority Review in the US for BRCA-Mutated HER2-Negative High-Risk Early Breast Cancer.

• FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA® (olaparib) as Adjuvant Treatment in BRCA-Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review

  11/30/2021

  FDA Accepts Regulatory Submission of Supplemental New Drug Application for LYNPARZA ® (olaparib) as Adjuvant Treatment in BRCA -Mutated, HER2-Negative High-Risk Early Breast Cancer and Grants Priority Review.

• NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca

  11/11/2021

  The National Comprehensive Cancer Network's Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer.

• AstraZeneca Advances Ambition to Redefine Care for Blood Cancer at ASH 2021

  11/5/2021

  AstraZeneca will present new data underscoring its commitment to transforming hematologic cancer care at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11 to 14, 2021.